PT  - JOURNAL ARTICLE
AU  - Joel C. Miller
AU  - Xueting Qiu
AU  - William P. Hanage
TI  - The risk of SARS-CoV-2 transmission in the healthcare setting and potential impact of cohorting strategies
AID  - 10.1101/2020.04.20.20073080
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.20.20073080
4099  - http://medrxiv.org/content/early/2020/04/23/2020.04.20.20073080.short
4100  - http://medrxiv.org/content/early/2020/04/23/2020.04.20.20073080.full
AB  - The threat of the COVID-19 pandemic of SARS-CoV-2 virus has grown since its start late last year. A customary response to a surge of a communicable disease is to separate healthcare systems into cohorts, such that patients with other conditions can be treated safely without risk of infection. A challenge with COVID-19 is the existence of currently asymptomatic infections, which without aggressive testing and isolation might enter the non-COVID-19 cohort either through unknowingly infected patients or health care workers. Using stochastic simulations we study the impacts of testing and personal protective equipment (PPE) use. In the base case without testing or PPE, healthcare is rapidly overwhelmed, and becomes a net contributor to the force of infection. We find that effective use of PPE by both HCW and patients can prevent this situation, while testing alone is less effective. We also find that even imperfectly effective use of PPE can provide substantial protection and decrease the force of infection. This illustrates the importance of maintaining supplies of PPE throughout healthcare systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementXQ and WPH were supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number U54GM088558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis is based on model construction and simulations. The specific details of our simulations are described in the Appendix. The simulations are scripted in Python and available to the open public. https://github.com/joelmiller/HospitalCOVID19